Ponatinib-induced symmetric dermatitis
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) which is used as a chemotherapeutic agent in the treatment of chronic myeloid leukemia. Despite being relatively less toxic than other older TKIs, it still has various adverse effects including skin rash. Cutaneous manifestations have v...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Indian Journal of Drugs in Dermatology |
| Subjects: | |
| Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=83;epage=85;aulast=Lohani |
| _version_ | 1797904925808656384 |
|---|---|
| author | Naman Lohani Gayathri Rajesh Anuradha Priyadarshini Murugan Sundaram |
| author_facet | Naman Lohani Gayathri Rajesh Anuradha Priyadarshini Murugan Sundaram |
| author_sort | Naman Lohani |
| collection | DOAJ |
| description | Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) which is used as a chemotherapeutic agent in the treatment of chronic myeloid leukemia. Despite being relatively less toxic than other older TKIs, it still has various adverse effects including skin rash. Cutaneous manifestations have varied presentations such as lichenoid, pityriasiform, ichthyosiform, and pityriasis rubra pilaris-like rash. We present here a 35-year-old male with chronic myeloid leukemia who developed a unique pattern of symmetrical rash to Ponatinib which was successfully treated with topical tacrolimus and reduction of dose of the drug. |
| first_indexed | 2024-04-10T09:56:46Z |
| format | Article |
| id | doaj.art-91b3895d1cc141e6b3d0a9caa899ca20 |
| institution | Directory Open Access Journal |
| issn | 2455-3972 |
| language | English |
| last_indexed | 2024-04-10T09:56:46Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Drugs in Dermatology |
| spelling | doaj.art-91b3895d1cc141e6b3d0a9caa899ca202023-02-16T12:19:44ZengWolters Kluwer Medknow PublicationsIndian Journal of Drugs in Dermatology2455-39722022-01-0182838510.4103/ijdd.ijdd_39_21Ponatinib-induced symmetric dermatitisNaman LohaniGayathri RajeshAnuradha PriyadarshiniMurugan SundaramPonatinib is a third-generation tyrosine kinase inhibitor (TKI) which is used as a chemotherapeutic agent in the treatment of chronic myeloid leukemia. Despite being relatively less toxic than other older TKIs, it still has various adverse effects including skin rash. Cutaneous manifestations have varied presentations such as lichenoid, pityriasiform, ichthyosiform, and pityriasis rubra pilaris-like rash. We present here a 35-year-old male with chronic myeloid leukemia who developed a unique pattern of symmetrical rash to Ponatinib which was successfully treated with topical tacrolimus and reduction of dose of the drug.http://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=83;epage=85;aulast=Lohanicutaneous adverse drug reactionsymmetrical dermatitistki |
| spellingShingle | Naman Lohani Gayathri Rajesh Anuradha Priyadarshini Murugan Sundaram Ponatinib-induced symmetric dermatitis Indian Journal of Drugs in Dermatology cutaneous adverse drug reaction symmetrical dermatitis tki |
| title | Ponatinib-induced symmetric dermatitis |
| title_full | Ponatinib-induced symmetric dermatitis |
| title_fullStr | Ponatinib-induced symmetric dermatitis |
| title_full_unstemmed | Ponatinib-induced symmetric dermatitis |
| title_short | Ponatinib-induced symmetric dermatitis |
| title_sort | ponatinib induced symmetric dermatitis |
| topic | cutaneous adverse drug reaction symmetrical dermatitis tki |
| url | http://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=83;epage=85;aulast=Lohani |
| work_keys_str_mv | AT namanlohani ponatinibinducedsymmetricdermatitis AT gayathrirajesh ponatinibinducedsymmetricdermatitis AT anuradhapriyadarshini ponatinibinducedsymmetricdermatitis AT murugansundaram ponatinibinducedsymmetricdermatitis |